Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605083 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Effector Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02605083: Clinical Trial Phase 1 study, sponsored by Effector Therapeutics.
NCT02605083 is a Phase 1 study that was terminated before completion, run by Effector Therapeutics. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02605083, a Phase 1 study, was terminated before completion, sponsored by Effector Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
Interventions
- DRUG eFT508
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-12-03 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 1 |
Why NCT02605083 stopped before completion
NCT02605083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 1 intervention - of which eFT508 is the first listed.
NCT02605083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02605083 about?
NCT02605083 is a clinical study titled "A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors". This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
What is the current status of trial NCT02605083?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-12-03. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT02605083?
The interventions under investigation include: eFT508 (DRUG).
Who is sponsoring clinical trial NCT02605083?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02605083's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI